Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Brain Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Temozolomide 154Bevacizumab 88Radiotherapy 75Radiation 23Magnetic Resonance Spectroscopy 23Lomustine 18Irinotecan 18pembrolizumab 17Surgical Procedures, Operative 16Carmustine 16Erlotinib Hydrochloride 12Nivolumab 11Specimen Handling 10Aminolevulinic Acid 10sargramostim 9Thalidomide 9Chemotherapy, Adjuvant 9Carboplatin 9Drug Therapy 8Immunoglobulin G 7Filgrastim 7Etoposide 7Disulfides 7Cilengitide 7Sunitinib 6Sorafenib 6O(6)-benzylguanine 6Cyclophosphamide 6antineoplaston AS 2-1 5antineoplaston A10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Glioblastoma × TPI-287 × Clear all
NCT02047214 2018-01-31

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

Cortice Biosciences, Inc.

Phase 2 Terminated
17 enrolled
CNS

Glioblastoma

NCT01113463 2016-10-31

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

M.D. Anderson Cancer Center

Phase 2 Terminated
17 enrolled 3 charts
CNS

Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡